Memantine

Introduction Overview

Generic Name

memantine

Brand Name

Namenda

Dosage Form

oral tablets

Drug Class

Miscellaneous central nervous system agents (NMDA receptor antagonist)

Pharmacokinetics

Absorption:
Memantine is well absorbed after oral administration with bioavailability approaching 100%. Peak plasma concentrations occur 3 to 7 hours after dosing, indicating relatively rapid absorption. Food does not affect the absorption of memantine significantly allowing it to be taken with or without food. The immediate-release formulation exhibits linear pharmacokinetics over the approved dosing range. In the extended-release XR formulation, drug release is prolonged, enabling once-daily dosing with steady absorption.

Distribution:
Memantine is moderately distributed into body tissues, displaying a steady-state volume of distribution of approximately 9 to 11 L/kg. It has moderate plasma protein binding (~45%), primarily to albumin, which is non-saturable and unlikely to cause significant drug interactions via displacement. Memantine readily crosses the blood-brain barrier achieving therapeutic concentrations within the central nervous system, its site of action. Cerebrospinal fluid concentrations are approximately 60-70% of plasma concentrations, which supports its CNS activity. Distribution can be affected in patients with altered body composition, but this has not been shown to have major clinical implications.

Metabolism:
Memantine undergoes minimal hepatic metabolism, with approximately 80% of the administered dose excreted unchanged in the urine. Minor metabolic pathways include oxidative deamination and hydroxylation mediated by cytochrome P450 enzymes; however, these are quantitatively insignificant. This limited hepatic metabolism minimizes potential drug-drug interactions involving CYP enzymes. In vitro studies have shown memantine does not significantly inhibit or induce major CYP isoforms.

Elimination:
Renal excretion is the primary route of elimination, with about 80% of memantine eliminated unchanged in urine via a combination of glomerular filtration and active tubular secretion. The elimination half-life averages 60 to 80 hours, allowing for once or twice daily dosing with steady-state achieved after 15 days of dosing. Factors that alter urinary pH significantly affect memantine's elimination as alkaline urine reduces renal clearance, increasing systemic exposure markedly (up to 80% reduction in clearance). Age-related decline in renal function also necessitates dose adjustments to prevent accumulation and toxicity. Memantine clearance is reduced in renal impairment, and dosage modifications are recommended accordingly.

Dosage Forms

Available Dosage Forms:
- Immediate-release oral tablets: 5 mg and 10 mg tablets
- Extended-release oral capsules (Namenda XR): available as 7 mg, 14 mg, 21 mg, and 28 mg capsules

Dosages for Adults and Adolescents:
Immediate-Release:
- Initial: 5 mg orally once daily
- Titration: Increase by 5 mg increments weekly
- Maintenance: 10 mg twice daily (maximum 20 mg per day)

Extended-Release (Namenda XR):
- Initial: 7 mg orally once daily
- Titration: Increase by 7 mg increments weekly
- Maintenance: 28 mg once daily (maximum dose)

Specific Patient Populations:
- Renal Impairment: Dose reductions are essential due to decreased clearance; for moderate impairment (creatinine clearance 30-50 mL/min), maximum dose is reduced, and for severe impairment (<30 mL/min) use is not recommended without specialist consultation.
- Elderly: No initial dose adjustment is required solely based on age, but renal function should guide dosing.
- Patients with hepatic impairment do not require dose adjustment as metabolism is minimal.
- Pediatric use: Safety and efficacy not established; no approved dosing.

Additional Considerations:
Namenda tablets can be administered with or without food. Extended-release capsules should be swallowed whole; however, for patients with swallowing difficulties, the capsules may be opened and their contents sprinkled on applesauce and administered immediately without chewing.

Mechanism Of Action

Memantine, the active agent in Namenda, is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, a subtype of glutamate receptor found in the central nervous system. The NMDA receptor is a ligand-gated ion channel implicated in synaptic plasticity and memory formation but, if overstimulated, can mediate excitotoxicity leading to neuronal injury or death. In Alzheimer's disease, excessive glutamate release and NMDA receptor hyperactivity contribute to neurodegeneration.

By binding to the NMDA receptor-associated ion channel in an open state, memantine blocks pathological activation without disrupting physiological glutamatergic neurotransmission. This voltage-dependent blockade preferentially inhibits the sustained, toxic influx of calcium ions while sparing normal synaptic transmission necessary for learning and memory processes. This selectivity distinguishes memantine from other NMDA antagonists that can cause intolerable side effects by blocking normal receptor activity.

Memantine’s modulation of glutamatergic neurotransmission reduces excitotoxic neuronal damage, providing neuroprotective effects thought to slow cognitive decline or improve symptoms in moderate to severe Alzheimer's disease. Clinical studies have demonstrated memantine’s ability to stabilize or modestly improve cognitive function, daily living activities, and behavioral symptoms in affected patients.

Compared with other Alzheimer's treatments like cholinesterase inhibitors (donepezil, rivastigmine), which increase acetylcholine neurochemistry, memantine targets glutamatergic pathways, providing a complementary mechanism. This mechanistic distinction supports combination therapy for enhanced therapeutic benefit. Ongoing research continues to explore memantine’s potential effects on synaptic plasticity and neuroinflammation relevant to dementia progression.

Pharmacological Actions

Non-competitive antagonism of NMDA-type glutamate receptors in the central nervous system.
Reduction of pathological calcium ion influx preventing excitotoxic neuronal injury.
Modulation of glutamatergic neurotransmission balancing excitatory signaling.
Neuroprotective effects potentially slowing progression of neuronal degeneration in Alzheimer's disease.
Improvement or stabilization of cognitive function and behavioral symptoms in moderate to severe dementia.
Minimal impact on physiological synaptic transmission due to voltage-dependent receptor blockade.
Does not inhibit acetylcholinesterase; complementary to cholinesterase inhibitors.
Crosses blood-brain barrier efficiently to exert central nervous system effects.
Does not significantly induce or inhibit hepatic cytochrome P450 enzymes, reducing drug interaction risk.
Renally excreted with kinetics allowing once or twice daily dosing.
Exhibits linear pharmacokinetics over therapeutic dose range.
Extended-release formulation allows for sustained plasma concentrations with improved adherence.
May modulate downstream signaling pathways linked to synaptic plasticity and neuroinflammation.
Potential synergistic effects when combined with other anti-dementia drugs.

Therapeutic Or Clinical Uses

Treatment of moderate to severe dementia of the Alzheimer's type.
Symptomatic management aimed at improving cognition, memory, and behavioral symptoms in Alzheimer's disease.
Used as monotherapy or adjunctive therapy with cholinesterase inhibitors like donepezil for enhanced efficacy.
Off-label uses explored in other neurodegenerative disorders involving excitotoxicity.
Potential neuroprotection in conditions characterized by glutamate-induced neuronal injury.
Slowing functional decline and improving activities of daily living in Alzheimer's disease patients.
Management of agitation and aggression associated with dementia.
Facilitating improved quality of life by stabilizing neurological function.
Adjunctive therapy during moderate to late stages of Alzheimer's when cholinesterase inhibitors may be insufficient.
Part of combination pharmacotherapy regimens targeting multiple neurotransmitter systems.
Explored use in vascular dementia and mixed dementia syndromes.
Potential use in mild cognitive impairment is under investigation but not FDA approved.
Treatment initiation can be considered after diagnosis to delay progression of cognitive symptoms.
May aid in behavioral symptom control reducing caregiver burden.

Side Or Adverse Effects

Dizziness, frequently reported but often mild and transient.
Headache commonly observed during dose titration period.
Confusion or transient worsening of cognitive symptoms in some patients.
Constipation noted possibly due to reduced gastrointestinal motility.
Hypertension reported rarely in clinical studies.
Somnolence or fatigue, potentially affecting daily activities.
Hallucinations or delusions reported uncommonly.
Restlessness or agitation may paradoxically occur.
Rare cases of hypersensitivity reactions including rash or angioedema.
Elevations in liver enzymes reported infrequently without clinical significance.
Urinary tract infections reported due to age and comorbidities rather than drug effect.
Increased risk of dizziness-related falls in elderly patients requiring precaution.
Nausea and vomiting are uncommon but possible gastrointestinal side effects.
Potential for impaired thinking or slowed reaction times impacting activities such as driving.
Overdose may result in severe neurological symptoms including stupor and seizures.

Precautions

Use with caution in patients with impaired renal function; dose adjustment recommended.
Monitor elderly patients for dizziness and balance disturbances to reduce fall risk.
Careful prescribing in patients with seizure disorders or history of epilepsy due to potential CNS effects.
Assess bladder function as memantine may cause urinary retention or worsen obstructive uropathy.
Avoid abrupt discontinuation to prevent rebound symptoms.
Dose titration should be gradual to minimize adverse reactions.
Evaluate potential interactions with concomitant medications affecting urinary pH.
Advise patients regarding possible dizziness and to avoid hazardous activities until stable.
Use cautiously during pregnancy as safety has not been established.
Breastfeeding mothers should consult healthcare providers due to unknown excretion into milk.
Monitor for hypersensitivity or allergic reactions post initiation.
Adjustment may be necessary in patients with hepatic impairment although minimal metabolism occurs.
Regular clinical assessment for therapeutic efficacy and tolerability is recommended.
Consider cognitive baseline assessment prior to initiation.
Be alert for signs of neuropsychiatric adverse events including confusion and hallucinations.

Warnings

Risk of impaired cognitive and motor functions requiring caution when driving or operating machinery.
Potential accumulation and toxicity in patients with decreased renal clearance or alkaline urine.
Serious allergic reactions, though rare, including swelling of face, lips, tongue, or throat necessitate immediate medical attention.
Drug clearance may be markedly reduced by medications or conditions that alkalinize urine, raising plasma memantine levels.
Concomitant use with other NMDA antagonists or centrally-acting drugs may potentiate CNS side effects.
Not a cure for Alzheimer's disease; expectations should be realistic regarding symptomatic benefit.
Use caution in patients with seizure disorders due to risk of lowering seizure threshold.
Abrupt withdrawal of extended-release formulations may lead to adverse events.
Overdose can cause severe neurological disturbances, necessitating emergency care.
Patients should inform physicians about all medications and supplements to avoid harmful interactions.
Use with caution in combination with acetazolamide or other carbonic anhydrase inhibitors affecting urine pH.
Careful titration is essential to reduce the incidence of adverse CNS effects.
Sudden changes in urinary pH due to illness or diet may unpredictably affect drug clearance.
Potential for increased plasma levels in elderly patients due to declining renal function.
Not recommended for use in pediatric populations due to lack of safety and efficacy data.

Contraindication

Known hypersensitivity to memantine or any components of the formulation.
History of allergic reactions to Namenda or memantine hydrochloride.
Use in patients with severe renal impairment without specialist supervision due to risk of accumulation.
Not indicated for treatment of mild cognitive impairment or other dementia forms without Alzheimer's diagnosis.
Contraindicated in concurrent use with strong NMDA receptor antagonists due to additive neurotoxicity.
Avoid in patients with urinary tract obstruction or severe bladder dysfunction unaddressed clinically.
Patients with contraindication to NMDA antagonism such as certain psychiatric conditions should avoid use.
Not recommended for pediatric patients due to unknown safety.
Discontinue if severe rash or signs of severe allergic reaction occur.
Avoid extended-release capsule administration via crushing, chewing, or opening except as directed.
Contraindicated in patients with history of worsening cognitive or behavioral symptoms linked to memantine.
Use contraindicated without dose adjustment in patients with urinary alkalinization caused by drugs or illness.
Avoid use in acute hypersensitivity reactions involving swelling of airway.
Contraindications may exist in patients on concomitant drugs affecting kidney function without monitoring.
Avoid use in patients with known sensitivity to inactive ingredients such as microcrystalline cellulose.

Drug Interactions

Amantadine may increase memantine pharmacological effects and risk of adverse reactions due to similar mechanisms.
Ketamine coadministration can potentiate NMDA receptor antagonism and CNS side effects.
Zonisamide may inhibit renal clearance of memantine, increasing plasma levels.
Dextromethorphan-containing cough suppressants can lead to additive NMDA antagonist effects causing CNS depression or hallucinations.
Medications that alkalinize urine such as sodium bicarbonate, potassium citrate, and citrate-containing preparations reduce memantine clearance by approximately 80%.
Glaucoma drugs acetazolamide and methazolamide, which alkalinize urine, can decrease memantine elimination enhancing toxicity risk.
Concomitant administration with other CNS depressants may increase dizziness, confusion, and sedation.
Drugs altering renal function or urinary pH may significantly impact memantine pharmacokinetics.
No significant cytochrome P450 mediated drug interactions have been reported due to minimal hepatic metabolism.
Use caution with diuretics that alter renal function or electrolytes impacting memantine excretion.
Combination with other anti-dementia agents like donepezil is generally safe but requires monitoring.
Potential interaction with carbonic anhydrase inhibitors necessitates dose adjustment or contraindication.
Avoid concomitant use with other NMDA antagonists to prevent excessive CNS blockade.
Monitoring of renal function and drug levels recommended when coadministering interacting agents.
Herbal products and over-the-counter supplements should be reviewed to prevent unknown pharmacodynamic interactions.

Preparations Of The Drug

Namenda immediate-release tablets contain memantine hydrochloride 5 mg or 10 mg per tablet.
Inactive ingredients include microcrystalline cellulose, colloidal silicon dioxide, talc, croscarmellose sodium, and magnesium stearate.
Tablet film coatings differ slightly between 5 mg (includes FD&C yellow #6 and FD&C blue #2) and 10 mg (contains iron oxide black) formulations.
Namenda XR extended-release capsules formulated with 7 mg, 14 mg, 21 mg, and 28 mg strengths for once-daily dosing.
Extended-release capsules should be swallowed whole or contents sprinkled on applesauce for those with swallowing difficulty.
Available under brand names Namenda and Namenda XR; generic memantine hydrochloride tablets also commercially available.
Manufactured by Merz Pharmaceuticals GmbH and distributed by Allergan USA, Inc.
Storage conditions: room temperature between 59°F and 77°F (15°C to 30°C), protected from moisture and heat.
Tablet formulations designed for oral administration with dosing flexibility for titration schedules.
Packaging includes bottles and blister packs suitable for outpatient prescription dispensing.
Not formulated for other routes of administration such as injectable or transdermal delivery.
Contains excipients that may cause hypersensitivity in susceptible individuals; review patient history before prescribing.
Dosage forms are designed to ensure consistent bioavailability and patient adherence.
Patient counseling includes guidance on proper administration and storage to maintain drug stability.
Pharmaceutical quality control ensures batch-to-batch consistency of active ingredient content and dissolution profile.